CEO Ian Akash Morrison Addresses Private Capital Leaders on Translational Oncology Innovation
Denver, CO – 2025 — Avesta Bio announced that CEO and Co-Founder Ian Akash Morrison was invited to speak at IPI Campden Denver, a leading global forum convening family offices, private investors, and institutional capital allocators.
IPI Campden events are recognized for bringing together select investment leaders to discuss emerging sectors, long-term capital strategy, and high-impact opportunities across industries. Mr. Morrison represented Avesta Bio in a session focused on innovation in biotechnology and the evolving landscape of translational medicine.
During his remarks, Mr. Morrison outlined Avesta Bio’s strategy to develop first-in-class therapies targeting maladaptive cellular stress-response and drug-resistance pathways implicated in tumor progression. The discussion addressed the scientific foundation of the company’s platform, its regulatory pathway toward Phase I clinical evaluation, and the disciplined execution model supporting its development roadmap.
“Long-term innovation in biotechnology requires patient capital aligned with scientific rigor,” said Ian Akash Morrison. “We appreciated the opportunity to engage with thoughtful investors who understand the importance of mechanistically driven development and responsible capital deployment in advancing meaningful therapies.”
The invitation reflects growing investor interest in translational oncology platforms that seek to address foundational biological drivers of cancer progression and therapeutic resistance. It also highlights Avesta Bio’s expanding engagement with private capital networks as the company advances toward key clinical milestones.
About Avesta Bio
Avesta Bio is a translational oncology company developing first-in-class therapies that target fundamental cellular stress-response and drug-resistance pathways. By correcting maladaptive cellular programs implicated in cancer progression, the company aims to deliver safe and effective treatments for patients with high-unmet-need malignancies.
The company is advancing its lead therapeutic program through global partnerships supporting IND-enabling studies, GMP manufacturing, and early-phase clinical development.
For more information, visit: www.avestabio.com